Sofinnova Partners has closed its second crossover fund at €725 [...]
Hemab Therapeutics has highlighted new clinical and preclinical data across [...]
The FDA has granted breakthrough therapy designation to Hemab [...]
Sofinnova Partners has closed its second crossover fund at €725 [...]
Hemab Therapeutics has highlighted new clinical and preclinical data across [...]
The FDA has granted breakthrough therapy designation to Hemab [...]